Kanamycin

Summary

Kanamycin (CHEMBL1384) is an approved small molecule (ATC J01GB04); indicated across 5 conditions including bacterial infectious disease and eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01GB04 (+2 more)
• Indications: 5 conditions
• Clinical trials: 5
• Chemistry: 484.5 Da · C18H36N4O11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1384
Name	Kanamycin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6032
ChEBI	CHEBI:17630
ATC	J01GB04, S01AA24, A07AA08
Molecular formula	C18H36N4O11
Molecular weight	484.5
InChIKey	SBUJHOSQTJFQJX-NOAMYHISSA-N

SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)N

IUPAC name: (2R,3S,4S,5R,6R)-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-3-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxyoxane-3,4,5-triol

Other ChEBI roles (chemical / environmental): bacterial metabolite.

Also known as: Kanamicina, Kanamycin, Kanamycine, Kanamycins, kanamycin, KANAMYCINE, kanamycin A, Kanamycin A, KANAMYCIN, kanamycina

Parent form; salt/anhydrous children: CHEMBL1446, CHEMBL4751482

Patent coverage: 89,868 distinct patent families (257,519 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Gap junction beta-2 protein, Gap junction alpha-1 protein, Beta-ketoacyl-[acyl-carrier-protein] synthase III.

Bioactivity

ChEMBL activities: 2 potent at pChembl ≥ 5 of 4 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0A6R0	5.17	IC50	6800	nM	CHEMBL_ACT_15139861
GJB2	5.03	IC50	9400	nM	CHEMBL_ACT_18552651

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
eye infectious disorder	4	MONDO:0043885	EFO:1001888
tuberculosis	3	MONDO:0018076	MONDO:0018076
multidrug-resistant tuberculosis	2	MONDO:0005861	EFO:0007381
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2/PHASE3	1
PHASE1	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00508690	PHASE3	COMPLETED	Trial of Antibiotic Prophylaxis in Elective Laparoscopic Colorectal Surgery: Oral and Systemic Versus Systemic Antibiotics
NCT02409290	PHASE3	COMPLETED	The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
NCT02454205	PHASE2/PHASE3	COMPLETED	An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis
NCT00816426	PHASE1	COMPLETED	Measurement of Anti-TB Drugs in Lung Tissue From Patients Having Surgery to Treat Tuberculosis
NCT00042289	Not specified	COMPLETED	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kana	CPIC	MT-RNR1		yes

PharmGKB also curates 4 clinical and 16 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).